Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 9/20 | 0.63 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.62 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.62 |
| ▸ | NPY4R | P50391 | 4/20 | 0.59 |
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 3/20 | 0.59 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30342384 | 0.98 | NTSR2 (0.62) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL30037831 | 0.93 | KISS1R (0.63) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL30844078 | 0.91 | BACE1 (0.59) | KISS1RNTSR2NTSR1 | |
| SCHEMBL30990788 | 0.89 | NPY4R (0.66) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL29447812 | 0.89 | NTSR2 (0.69) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL29770017 | 0.89 | NTSR2 (0.68) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL30038033 | 0.88 | KISS1R (0.61) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL30038639 | 0.88 | KISS1R (0.60) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL31462098 | 0.87 | NTSR1 (0.57) | KISS1RNTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL29362467 | 0.86 | NTSR2 (0.63) | KISS1RNTSR2NTSR1NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326310-A1 | USE OF AVIPTADIL ALONE OR IN COMBINATION WITH ALPHA LIPOIC ACID AS A THERAPEUTIC MEDICAMENT FOR POST-VIRAL INFECTION SYNDROME | AdVita Lifescience AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022224172-A1 | USE OF AVIPTADIL ALONE OR IN COMBINATION WITH ALPHA LIPOIC ACID AS A THERAPEUTIC MEDICAMENT FOR POST-VIRAL INFECTION SYNDROME | ADVITA LIFESCIENCE AG (CH) | 2022-10-27 | — | — | WO | disclosed |